Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00052416 · ClinicalTrials.gov registry record · Phase 1
Thalidomide in Treating Patients With Asymptomatic, Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
A Phase 1 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00052416: Completed Phase 1 study, sponsored by Beth Israel Deaconess Medical Center.
NCT00052416 is a Phase 1 study that has completed, run by Beth Israel Deaconess Medical Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00052416, a Phase 1 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to determine the effectiveness of thalidomide in treating patients who have asymptomatic, indolent non-Hodgkin's lymphoma or chronic lymphocytic leukemia.
Interventions
- DRUG thalidomide
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-10 |
| Est. Completion | 2003-01 |
| Phase | Phase 1 |
What the finished NCT00052416 record still lists
NCT00052416 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which thalidomide is the first listed.
NCT00052416 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00052416 about?
NCT00052416 is a clinical study titled "Thalidomide in Treating Patients With Asymptomatic, Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia". RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to determine the effectiveness of thalidomide in treating patients who have asymptomatic, indolent non-Hodgkin's lymphoma or chronic lymphocytic leukemia.
What is the current status of trial NCT00052416?
This trial is currently completed. It is a Phase 1 study. The study started on 2002-10. Estimated completion is 2003-01.
What interventions are being tested in trial NCT00052416?
The interventions under investigation include: thalidomide (DRUG).
Who is sponsoring clinical trial NCT00052416?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia